Dauntless Pharmaceuticals
12390 El Camino Real
Suite 170
San Diego
California
92130
United States
Tel: 858-999-3053
Website: http://www.dauntlessph.com/
About Dauntless Pharmaceuticals
Dauntless provides a better way to develop drugs.The traditional biotech company holds numerous assets at various stages of development, and its investors, management, labs, and staff collectively share interest in all company assets. In contrast, Dauntless uses a one-asset, one-company model. Each asset is held in a separate holding company, with Dauntless managing the development of each asset and employing expert consultants who specialize in the unique requirements of a given asset. This innovative approach facilitates operational efficiency, drug development speed, and a simplified business development structure. The result: lower costs, shorter timelines, higher returns.
YEAR FOUNDED:
2015
LEADERSHIP:
President and CEO: Joel F. Martin, PhD
Vice President, Development: Olivier Laurent, PhD
Vice President, Regulatory Affairs and Quality: Michelle Mazzoni, PhD, RAC
Director of Clinical Operations: Mark Daniels
PIPELINE:
Please click here for Dauntless' pipeline.
3 articles about Dauntless Pharmaceuticals
-
FDA Grants Orphan Drug Designation to Dauntless Pharma's DP1038 for the Treatment of Acromegaly
1/30/2018
The FDA grants orphan drug status to promote the development of novel products to treat conditions affecting fewer than 200,000 people in the United States.
-
Dauntless Pharma Announces Positive Data From Phase I Study Investigating Octreotide Formulation For Intranasal Delivery
5/4/2017
-
Dauntless Pharma Announces Initiation Of Phase I Clinical Trial Of Octreotide Formulation For Intranasal Delivery
2/16/2017